Literature DB >> 34215014

Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment.

Taisa J Kohut1, Melissa A Gilbert2, Kathleen M Loomes1,3.   

Abstract

Alagille syndrome (ALGS) is an autosomal dominant disorder caused by pathogenic variants in JAG1 or NOTCH2, which encode fundamental components of the Notch signaling pathway. Clinical features span multiple organ systems including hepatic, cardiac, vascular, renal, skeletal, craniofacial, and ocular, and occur with variable phenotypic penetrance. Genotype-phenotype correlation studies have not yet shown associations between mutation type and clinical manifestations or severity, and it has been hypothesized that modifier genes may modulate the effects of JAG1 and NOTCH2 pathogenic variants. Medical management is supportive, focusing on clinical manifestations of disease, with liver transplant indicated for severe pruritus, liver synthetic dysfunction, portal hypertension, bone fractures, and/or growth failure. New therapeutic approaches are under investigation, including ileal bile acid transporter (IBAT) inhibitors and other approaches that may involve targeted interventions to augment the Notch signaling pathway in involved tissues. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34215014     DOI: 10.1055/s-0041-1730951

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  3 in total

1.  Tamoxifen Ameliorates Cholestatic Liver Fibrosis in Mice: Upregulation of TGFβ and IL6 Is a Potential Protective Mechanism.

Authors:  Dino Šisl; Darja Flegar; Maša Filipović; Petra Turčić; Pavao Planinić; Alan Šućur; Nataša Kovačić; Danka Grčević; Tomislav Kelava
Journal:  Biomedicines       Date:  2022-05-23

2.  Outside influence: The extrahepatic duct as a source for bile duct regeneration.

Authors:  Emma R Andersson
Journal:  Hepatology       Date:  2022-03       Impact factor: 17.298

3.  Use of funded multicenter prospective longitudinal databases to inform clinical trials in rare diseases-Examination of cholestatic liver disease in Alagille syndrome.

Authors:  Benjamin L Shneider; Binita M Kamath; John C Magee; Nathan P Goodrich; Kathleen M Loomes; Wen Ye; Cathie Spino; Estella M Alonso; Jean P Molleston; Jorge A Bezerra; Kasper S Wang; Saul J Karpen; Simon P Horslen; Stephen L Guthery; Philip Rosenthal; Robert H Squires; Ronald J Sokol
Journal:  Hepatol Commun       Date:  2022-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.